Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 21Terminated 7Active not recruiting 2Withdrawn 1Unknown 1Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 19Recurrence 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms, Plasma Cell 3Mycosis Fungoides 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Lung Neoplasms 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Sezary Syndrome 1Ovarian Neoplasms 1Nasopharyngeal Carcinoma 1Myelodysplastic Syndromes 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Leukemia, Plasma Cell 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Rituximab 5Peripheral Blood Stem Cell Transplantation 4Cyclophosphamide 4ibrutinib 2fludarabine phosphate 2Tacrolimus 2Pentetic Acid 2Methotrexate 2Melphalan 2Lenalidomide 2Etoposide 2Doxorubicin 2Dexamethasone 2Cytarabine 2Carmustine 2umbralisib 1ublituximab 1sargramostim 1romidepsin 1ethanolamine oleate 1antineoplaston AS 2-1 1antineoplaston A10 1Whole-Body Irradiation 1Vincristine 1Trimethoprim, Sulfamethoxazole Drug Combination 1Trimethoprim 1Transplantation 1Thiotepa 1Thalidomide 1Sulfamethoxazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Waldenstrom Macroglobulinemia × Bortezomib × Clear all
NCT00723658 2015-03-06

S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia

SWOG Cancer Research Network

Phase 2 Withdrawn
Lymphoid

Lymphoma, Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡